242 related articles for article (PubMed ID: 36475868)
1. Epoxyeicosatrienoic acid administration or soluble epoxide hydrolase inhibition attenuates renal fibrogenesis in obstructive nephropathy.
Noh MR; Jang HS; Salem FE; Ferrer FA; Kim J; Padanilam BJ
Am J Physiol Renal Physiol; 2023 Feb; 324(2):F138-F151. PubMed ID: 36475868
[TBL] [Abstract][Full Text] [Related]
2. Pharmacological inhibition of soluble epoxide hydrolase prevents renal interstitial fibrogenesis in obstructive nephropathy.
Kim J; Yoon SP; Toews ML; Imig JD; Hwang SH; Hammock BD; Padanilam BJ
Am J Physiol Renal Physiol; 2015 Jan; 308(2):F131-9. PubMed ID: 25377915
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of soluble epoxide hydrolase prevents renal interstitial fibrosis and inflammation.
Kim J; Imig JD; Yang J; Hammock BD; Padanilam BJ
Am J Physiol Renal Physiol; 2014 Oct; 307(8):F971-80. PubMed ID: 25164080
[TBL] [Abstract][Full Text] [Related]
4. Soluble epoxide hydrolase regulates hydrolysis of vasoactive epoxyeicosatrienoic acids.
Yu Z; Xu F; Huse LM; Morisseau C; Draper AJ; Newman JW; Parker C; Graham L; Engler MM; Hammock BD; Zeldin DC; Kroetz DL
Circ Res; 2000 Nov; 87(11):992-8. PubMed ID: 11090543
[TBL] [Abstract][Full Text] [Related]
5. Genetic disruption of soluble epoxide hydrolase is protective against streptozotocin-induced diabetic nephropathy.
Chen G; Xu R; Wang Y; Wang P; Zhao G; Xu X; Gruzdev A; Zeldin DC; Wang DW
Am J Physiol Endocrinol Metab; 2012 Sep; 303(5):E563-75. PubMed ID: 22739108
[TBL] [Abstract][Full Text] [Related]
6. Expression of soluble epoxide hydrolase in renal tubular epithelial cells regulates macrophage infiltration and polarization in IgA nephropathy.
Wang Q; Liang Y; Qiao Y; Zhao X; Yang Y; Yang S; Li B; Zhao Q; Dong L; Quan S; Tian R; Liu Z
Am J Physiol Renal Physiol; 2018 Oct; 315(4):F915-F926. PubMed ID: 29717935
[TBL] [Abstract][Full Text] [Related]
7. Epoxyeicosatrienoic and dihydroxyeicosatrienoic acids dilate human coronary arterioles via BK(Ca) channels: implications for soluble epoxide hydrolase inhibition.
Larsen BT; Miura H; Hatoum OA; Campbell WB; Hammock BD; Zeldin DC; Falck JR; Gutterman DD
Am J Physiol Heart Circ Physiol; 2006 Feb; 290(2):H491-9. PubMed ID: 16258029
[TBL] [Abstract][Full Text] [Related]
8. Soluble epoxide hydrolase contamination of specific catalase preparations inhibits epoxyeicosatrienoic acid vasodilation of rat renal arterioles.
Gauthier KM; Olson L; Harder A; Isbell M; Imig JD; Gutterman DD; Falck JR; Campbell WB
Am J Physiol Renal Physiol; 2011 Oct; 301(4):F765-72. PubMed ID: 21753077
[TBL] [Abstract][Full Text] [Related]
9. Arachidonic acid cytochrome P450 epoxygenase pathway.
Spector AA
J Lipid Res; 2009 Apr; 50 Suppl(Suppl):S52-6. PubMed ID: 18952572
[TBL] [Abstract][Full Text] [Related]
10. Reno-protective mechanisms of epoxyeicosatrienoic acids in cardiovascular disease.
Elmarakby AA
Am J Physiol Regul Integr Comp Physiol; 2012 Feb; 302(3):R321-30. PubMed ID: 22116511
[TBL] [Abstract][Full Text] [Related]
11. Attenuation of cisplatin-induced renal injury by inhibition of soluble epoxide hydrolase involves nuclear factor κB signaling.
Liu Y; Webb HK; Fukushima H; Micheli J; Markova S; Olson JL; Kroetz DL
J Pharmacol Exp Ther; 2012 Jun; 341(3):725-34. PubMed ID: 22414856
[TBL] [Abstract][Full Text] [Related]
12. Genetic deletion of soluble epoxide hydrolase attenuates inflammation and fibrosis in experimental obstructive nephropathy.
Chiang CW; Lee HT; Tarng DC; Kuo KL; Cheng LC; Lee TS
Mediators Inflamm; 2015; 2015():693260. PubMed ID: 25688176
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of soluble epoxide hydrolase does not protect against endotoxin-mediated hepatic inflammation.
Fife KL; Liu Y; Schmelzer KR; Tsai HJ; Kim IH; Morisseau C; Hammock BD; Kroetz DL
J Pharmacol Exp Ther; 2008 Dec; 327(3):707-15. PubMed ID: 18815352
[TBL] [Abstract][Full Text] [Related]
14. Epoxide hydrolase 1 (EPHX1) hydrolyzes epoxyeicosanoids and impairs cardiac recovery after ischemia.
Edin ML; Hamedani BG; Gruzdev A; Graves JP; Lih FB; Arbes SJ; Singh R; Orjuela Leon AC; Bradbury JA; DeGraff LM; Hoopes SL; Arand M; Zeldin DC
J Biol Chem; 2018 Mar; 293(9):3281-3292. PubMed ID: 29298899
[TBL] [Abstract][Full Text] [Related]
15. Renal Ischemia/Reperfusion Injury in Soluble Epoxide Hydrolase-Deficient Mice.
Zhu Y; Blum M; Hoff U; Wesser T; Fechner M; Westphal C; Gürgen D; Catar RA; Philippe A; Wu K; Bubalo G; Rothe M; Weldon SM; Dragun D; Schunck WH
PLoS One; 2016; 11(1):e0145645. PubMed ID: 26727266
[TBL] [Abstract][Full Text] [Related]
16. Soluble epoxide hydrolase gene deletion is protective against experimental cerebral ischemia.
Zhang W; Otsuka T; Sugo N; Ardeshiri A; Alhadid YK; Iliff JJ; DeBarber AE; Koop DR; Alkayed NJ
Stroke; 2008 Jul; 39(7):2073-8. PubMed ID: 18369166
[TBL] [Abstract][Full Text] [Related]
17. Preservation of epoxyeicosatrienoic acid bioavailability prevents renal allograft dysfunction and cardiovascular alterations in kidney transplant recipients.
Duflot T; Laurent C; Soudey A; Fonrose X; Hamzaoui M; Iacob M; Bertrand D; Favre J; Etienne I; Roche C; Coquerel D; Le Besnerais M; Louhichi S; Tarlet T; Li D; Brunel V; Morisseau C; Richard V; Joannidès R; Stanke-Labesque F; Lamoureux F; Guerrot D; Bellien J
Sci Rep; 2021 Feb; 11(1):3739. PubMed ID: 33580125
[TBL] [Abstract][Full Text] [Related]
18. Dual soluble epoxide hydrolase inhibitor/PPAR-γ agonist attenuates renal fibrosis.
Stavniichuk A; Hye Khan MA; Yeboah MM; Chesnik MA; Jankiewicz WK; Hartmann M; Blöcher R; Kircher T; Savchuk O; Proschak E; Imig JD
Prostaglandins Other Lipid Mediat; 2020 Oct; 150():106472. PubMed ID: 32569747
[TBL] [Abstract][Full Text] [Related]
19. Vascular pharmacology of epoxyeicosatrienoic acids.
Pfister SL; Gauthier KM; Campbell WB
Adv Pharmacol; 2010; 60():27-59. PubMed ID: 21081214
[TBL] [Abstract][Full Text] [Related]
20. Increases in levels of epoxyeicosatrienoic and dihydroxyeicosatrienoic acids (EETs and DHETs) in liver and heart in vivo by 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) and in hepatic EET:DHET ratios by cotreatment with TCDD and the soluble epoxide hydrolase inhibitor AUDA.
Diani-Moore S; Ma Y; Gross SS; Rifkind AB
Drug Metab Dispos; 2014 Feb; 42(2):294-300. PubMed ID: 24311719
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
